Patents Assigned to 3-D MATRIX, LTD.
  • Patent number: 11260072
    Abstract: Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: March 1, 2022
    Assignee: 3-D Matrix, Ltd.
    Inventors: Takahiro Ochiya, Tomohiro Fujiwara
  • Publication number: 20210299326
    Abstract: Gamma ray and e-beam irradiation provided efficient sterilization of certain self-assembling peptides (including RADA16 in solution) without substantial degradation of the major peptide, while, e.g., another self-assembly peptide, QLEL12 was significantly degraded following irradiation. Irradiation sterilization enhances the rheological property of, for example, RADA16 hydrogel once applied to tissue at a physiological pH. The rheological property increase can result in higher efficacy in a variety of biomedical applications.
    Type: Application
    Filed: March 30, 2021
    Publication date: September 30, 2021
    Applicant: 3-D Matrix, Ltd.
    Inventors: Marika G. Rioult, Eun Seok Gil, Elton Aleksi, Naoki Yamamoto
  • Patent number: 11090398
    Abstract: Methods and devices for sterilizing viscous peptide compositions which have shear thinning rheological properties at high concentrations.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: August 17, 2021
    Assignee: 3-D Matrix, Ltd.
    Inventors: Eun Seok Gil, Karl Patrick Gilbert
  • Publication number: 20210215713
    Abstract: The present invention to a method, a kit, etc., for predicting the response BNCT using a BSH-related medicine-containing boron preparation and a BPA-containing boron preparation, the method and kit being characterized by examining the expression of CD44, a translation-related factor and/or LAT1 in cancer cells of a sample. When the expression of the CD44 or translation-related factor in the cancer cells of the sample is high, it can be predicted that the BNCT using the BSSH-related medicine-containing boron preparation is likely to be responsive. When the expression of the LAT1 in the cancer cells of the sample is high, it can be predicted that the BNCT using the BPA-containing boron preparation is likely to be responsive.
    Type: Application
    Filed: February 8, 2019
    Publication date: July 15, 2021
    Applicant: 3-D MATRIX, LTD.
    Inventors: Hideki MATSUI, Atsushi FUJIMURA
  • Patent number: 10961274
    Abstract: Self-assembling peptides comprising non-ionic polar amino acids for anti-adhesion are provided herein. Compositions, peptide solutions and macroscopic scaffolds of self-assembling peptides consisting essentially of non-ionic, polar amino acids are provided to prevent adhesion or to provide anti-adhesion properties. Particular peptides include those consisting essentially of, serine, threonine, tyrosine, cysteine, glutamine, asparagine, methionine, tryptophan, hydroxy-proline, and combinations thereof. Methods and kits are also provided.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 30, 2021
    Assignee: 3-D Matrix, Ltd.
    Inventors: Eun Seok Gil, Marc Rioult, Keiji Nagano, Karl Patrick Gilbert, Toshiro Kiyofuji, Yuya Hasegawa
  • Patent number: 10835637
    Abstract: The present invention relates to a triblock copolymer having a polyethylene glycol-poly(D,L-lactide)-polyethylene glycol skeleton.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: November 17, 2020
    Assignees: 3-D Matrix, Ltd. (Tokyo, Japan), Tokyo University of Science Foundation
    Inventors: Hidenori Otsuka, Daisuke Matsukuma, Noriaki Matsuda
  • Patent number: 10814038
    Abstract: Combination compositions comprising self-assembling peptides and payload agents, and methods of making and using such compositions, are described.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: October 27, 2020
    Assignees: 3-D Matrix, Ltd., Vicus Therapeutics, LLC
    Inventors: John Maki, Eun Seok Gil, Lisa Spirio
  • Patent number: 10793307
    Abstract: The enclosed disclosure describes, among other things, a method including the steps of a first deaerating step in which a mixture comprising peptides is deaerated by lowering the pressure, filtering the mixture through a sterilizing filter; and a second deaerating step, in which the filtrate is deaerated by vibration and lowering the pressure.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: October 6, 2020
    Assignee: 3-D Matrix, Ltd.
    Inventors: Masahiro Nohara, Yuya Hasegawa
  • Patent number: 10682441
    Abstract: Compositions, peptide solutions and macroscopic scaffolds of self-assembling peptides consisting essentially of non-ionic, polar amino acids are provided. Particular peptides include those comprising or consisting essentially of serine, threonine, tyrosine, cysteine, glutamine, asparagine, methionine, tryptophan, hydroxy-proline, and combinations thereof. Methods of sterilizing the self-assembling peptides, and scaffolds comprising the peptides are also provided.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: June 16, 2020
    Assignee: 3-D Matrix, Ltd.
    Inventors: Eun Seok Gil, Marc Rioult, Keiji Nagano, Karl Partick Gilbert, Toshiro Kiyofuji, Yuya Hasegawa
  • Patent number: 10654893
    Abstract: The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc. that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy).
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: May 19, 2020
    Assignee: 3-D Matrix, Ltd.
    Inventors: Eun Seok Gil, Karl Gilbert, Manav Mehta
  • Patent number: 10596265
    Abstract: A nanogel comprising a self-organizing peptide, a chitosan and polyethylene glycol is described.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: March 24, 2020
    Assignees: 3-D Matrix, Ltd., Tokyo University of Science Foundation
    Inventors: Hidenori Otsuka, Daisuke Matsukuma
  • Patent number: 10596225
    Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: March 24, 2020
    Assignee: 3-D Matrix, Ltd.
    Inventors: Kentaro Takamura, Satoshi Gojo, Satoru Kobayashi
  • Patent number: 10576123
    Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: March 3, 2020
    Assignee: 3-D Matrix, Ltd.
    Inventors: Kentaro Takamura, Satoshi Gojo, Satoru Kobayashi
  • Patent number: 10369237
    Abstract: Methods and devices for sterilizing viscous peptide compositions which have shear thinning rheological properties at high concentrations.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: August 6, 2019
    Assignee: 3-D Matrix, LTD.
    Inventors: Eun Seok Gil, Karl Patrick Gilbert
  • Patent number: 10337012
    Abstract: The invention provides a method and composition for the treatment, prevention, and diagnosis of cancer containing or derived from cancer stem cells.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: July 2, 2019
    Assignees: 3-D Matrix, Ltd., National Cancer Center
    Inventor: Takahiro Ochiya
  • Patent number: 10286200
    Abstract: A syringe and a syringe set are provided. The syringe can be readily distinguished from other syringes only by viewing a tip of the syringe. The syringe includes a tip provided at an end of a barrel body to be filled with a medicine and having an outer diameter of 4.315 mm to 6 mm, a peripheral wall provided around the tip concentrically with the tip, and a helical rib formed on an inner the of the peripheral wall or an outer face of the tip.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: May 14, 2019
    Assignees: TAISEI KAKO CO., LTD., FUSO PHARMACEUTICAL INDUSTRIES, LTD., 3-D Matrix, Ltd.
    Inventors: Taiji Horita, Ippei Matsumoto, Tomoyuki Sonoyama, Fukumitsu Nishioka, Shoujirou Tanioka, Masahiro Nohara, Kiyoshi Takano
  • Patent number: 10245299
    Abstract: Materials and methods for treatment of pulmonary bulla are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. A hydrogel barrier may be provided at the target site in order to treat the pulmonary bulla.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: April 2, 2019
    Assignee: 3-D Matrix, Ltd.
    Inventors: Manav Mehta, Hisashi Tsukada, Eun Seok Gil, Karl Gilbert, Satoru Kobayashi
  • Publication number: 20180250435
    Abstract: The present invention relates to a triblock copolymer having a polyethylene glycol-poly(D,L-lactide)-polyethylene glycol skeleton.
    Type: Application
    Filed: August 23, 2016
    Publication date: September 6, 2018
    Applicants: 3-D Matrix, Ltd., Tokyo University of Science Foundation
    Inventors: Hidenori Otsuka, Daisuke Matsukuma, Noriaki Matsuda
  • Patent number: D833001
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: November 6, 2018
    Assignees: ANEST IWATA CORPORATION, 3-D MATRIX, LTD.
    Inventor: Hidetoshi Ishikawa
  • Patent number: D847975
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: May 7, 2019
    Assignees: ANEST IWATA CORPORATION, 3-D MATRIX, LTD.
    Inventor: Hidetoshi Ishikawa